Physician profile
Holly A Tucker
NPI 1437100195
$9,294.96
in general payments reported to CMS, 2019-2025
25 companies · $2,966 in 2025
The $2,966 reported for 2025 was more than what 99% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $968 · 2022: $2,582 · 2023: $1,910 · 2024: $869 · 2025: $2,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,141 · Education: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,140.89 |
| Education | $604.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,840.73 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,812.13 | 2021-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $1,269.12 | 2021-2025 | |
| Galderma Laboratories, L.P. | $624.21 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $564.31 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $552.69 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $398.25 | 2021-2025 | |
| Incyte Corporation | $350.80 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $336.23 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $319.32 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $280.35 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $185.15 | 2022-2025 | Sotyktu |
| Organon LLC | $149.06 | 2025 | Vtama |
| Ucb, INC. | $147.20 | 2025 | Bimzelx |
| Amgen INC. | $141.78 | 2022-2025 | Otezla, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.87 | 2023-2025 | Spevigo |
| Paratek Pharmaceuticals, INC. | $34.94 | 2025 | Nuzyra |
| Journey Medical Corporation | $29.78 | 2023 | |
| Dermavant Sciences, INC. | $29.25 | 2023 | Vtama |
| Fresenius Kabi USA, LLC | $27.31 | 2023 | |
| Biofrontera INC. | $24.34 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.39 | 2025 | Cabtreo |
| Arcutis Biotherapeutics, INC. | $21.66 | 2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $19.84 | 2021 | |
| Botanix Sb INC | $15.25 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.